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Painful diabetic neuropathy (PDN) is one of the most common complications in the early
stage of diabetes mellitus (DM). Endomorphin-2 (EM2) selectively activates the µ-opioid
receptor (MOR) and subsequently induces antinociceptive effects in the spinal dorsal
horn. However, the effects of EM2-MOR in PDN have not yet been clarified in the spinal
dorsal horn. Therefore, we aimed to explore the role of EM2-MOR in the pathogenesis
of PDN. The main findings were the following: (1) streptozotocin (STZ)-induced diabetic
rats exhibited hyperglycemia, body weight loss and mechanical allodynia; (2) in the spinal
dorsal horn, the expression levels of EM2 and MOR decreased in diabetic rats; (3) EM2
protein concentrations decreased in the brain, lumbar spinal cord and cerebrospinal fluid
(CSF) in diabetic rats but were unchanged in the plasma; (4) the frequency but not the
amplitude of spontaneous excitatory postsynaptic currents (sEPSCs) was significantly
higher in diabetic rats than in control rats; and (5) intrathecal injection of EM2 for 14 days
in the early stage of PDN partially alleviated mechanical allodynia and reduced MOR
expression in diabetic rats. Our results demonstrate that the EM2-MOR signal may be
involved in the early stage of PDN.
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INTRODUCTION
Diabetic neuropathy is the most common complication of diabetes mellitus (DM). It is known
that painful diabetic neuropathy (PDN) in diabetic patients and animal models occurs at
the early stage of the disease prior to the appearance of overt clinical symptoms (Ziegler,
2008). In previous studies, streptozotocin (STZ)-induced type 1 diabetic rats developed
PDN as early as 2 weeks after STZ injection (Malcangio and Tomlinson, 1998; Kou et al.,
2014; Castelli et al., 2016). However, the mechanism underlying PDN remains unclear, and
effective drugs for PDN management in diabetes remain unavailable (Jaspan et al., 1983;
Bouhassira et al., 2014; Schreiber et al., 2015). Although PDN could benefit from opioid-based
therapies, the clinical use of opioids has been hampered by significant side effects, such as
gastrointestinal complications, respiratory depression, tolerance and dependence with long-
term use (Zhao et al., 2010; Wu et al., 2011; Banafshe et al., 2014). Therefore, searching for
more selective and effective therapeutics with fewer side effects is important for treating PDN.
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As endogenous opioid peptides, the endomorphins (EMs),
EM1 (Tyr-Pro-Trp-Phe-NH2) and EM2 (Tyr-Pro-Phe-Phe-
NH2) are highly selective for the µ-opioid receptor (MOR;
Champion et al., 1997; Hosohata et al., 1998; Wang et al.,
2003). Both EM1 and EM2 have been suggested to be naturally
occurring peptides with remarkable antinociceptive properties
and less adverse effects than opioids (Czapla et al., 2000;
Varamini and Toth, 2013). Importantly, previous studies have
confirmed that morphine and EM differentially regulated MOR
mRNA expression and function (McConalogue et al., 1999;
Yu et al., 2003), suggesting that EMs might provide excellent
therapeutic potential benefits as replacements for morphine-like
opioids.
It has been shown that EM1-immunoreactivity (-ir) is
primarily restricted to the brain, but EM2-ir is found primarily in
the superficial layer of the spinal dorsal horn, which is considered
to be the fundamental area in nociceptive transmission
modulation in the central nervous system (CNS; Martin-Schild
et al., 1998, 1999; Pierce and Wessendorf, 2000). Importantly, a
significant effect of regulating nociceptive transmission of EM2
has been documented in the spinal cord (Labuz et al., 2003). In
the spinal dorsal horn, EM2 plays a more efficient analgesic role
than that of EM1 in several animal models of pain, including
neuropathic pain (Tseng et al., 2000). In response to EM2,
the antinociceptive effect is blocked by MOR antagonists, and
EM2 treatment fails to induce significant antinociceptive effects
in MOR knockout mice, indicating that the antinociceptive
activities of EM2 are restricted to the MOR in the spinal
cord (Narita et al., 1999; Tseng et al., 2000). Therefore, we
hypothesized that EM2 and MOR may be involved in PDN in
the spinal cord.
It has been noted that the level of peripheral EMs was
suppressed in diabetic patients compared with healthy volunteers
(Xia et al., 2010). In the type 1 diabetic mouse, previous results
have demonstrated that the inhibitory effects of EM2 on colonic
motility were attenuated, but the effects of EM1 were unchanged,
indicating that EM2 may play a more important role in diabetes
(Wang et al., 2008). Reports have suggested that the effects of
EM2were reduced in PDN (Chen et al., 2002), and this result may
be due to decreased EM2,MOR or both. However, the underlying
mechanism of EM2 and MOR in PDN is still unclear.
Based on these considerations, we address the hypothesis
that EM2 and MOR may be associated with the pathogenesis
of PDN in the spinal dorsal horn. Changes in EM2 and
MOR were examined in diabetic rats by immunohistochemistry,
enzyme-linked immunosorbent assay (ELISA), Western blotting
and electrophysiological techniques. In addition, we applied
intrathecal infusions of EM2 for 14 days in diabetic rats. We
attempted to test the hypothesis that the EM2-MOR signal may
be associated with the development of PDN.
MATERIALS AND METHODS
Experimental Animals
All animal studies were conducted using approved protocols
and carried out in accordance with the Principles of Laboratory
Animal Care (NIH Publication no. 85-23, revised 1985).
The Animal Care and Use Committees of the Fourth
Military Medical University reviewed and approved all
protocols. Male Sprague-Dawley rats weighing 220–250 g
purchased from Laboratory Animal Resources of the Fourth
Military Medical University were utilized and given a single
intraperitoneal injection of STZ (60 mg/kg, Sigma, St. Louis,
MO, USA), which was freshly dissolved in ice-cold sodium
citrate (pH 4.5). Diabetes was confirmed on the 3rd day by
measurements of blood glucose concentrations in samples
obtained from the tail vein using a strip-operated reflectance
meter (Active; Roche Diagnostics, Mannheim, Germany).
Only rats with blood glucose concentrations greater than
20 mM were further used. Citrate buffer-treated rats were
used as a normoglycemic control (blood glucose less than
12 mM). All animals were housed in standard conditions
(12 h light/dark cycles) with water and food available
ad libitum.
Measurement of Hindpaw Withdrawal
Threshold
Experiments were performed on the STZ-treated rats and
saline-treated control rats, according to our protocols reported
previously (Mei et al., 2011; Kou et al., 2013, 2014). To quantify
the mechanical sensitivity, rats were placed in individual plastic
boxes and allowed to acclimate for 30 min. A series of calibrated
von Frey filaments (Stoelting, Kiel, WI, USA) ranging from 0.4
to 60.0 g were applied to the plantar surface of the hindpaw
of rats with a sufficient force to bend the filaments for 5 s
or until the paw withdrew. There was a 15 s interval between
applications that allowed the animal to return to a relatively
inactive position. In the presence of a response, the filament of
next lower force was applied. The filament of next greater force
was applied when a response was absent. A positive response
was determined by a sharp withdrawal of the paw. Each filament
was applied 10 times, and the minimal value that caused a
response at least six times was recorded as the paw withdrawal
threshold (PWT). All behavioral studies were performed under
blind conditions.
Immunohistochemistry
Rats (n = 6 in each group) were deeply anesthetized by an
intraperitoneal injection of pentobarbital (50 mg/kg, i.p.) and
perfused for immunohistochemistry. After perfusion, lumbar
segments (L4–L6) of the spinal cord were removed, post-
fixed and placed in 30% (w/v) sucrose solution for 24 h
at 4◦C. Transverse sections of the spinal cord (25 µm)
were incubated in blocking solution (5% v/v normal goat
serum) for 1 h at room temperature and then incubated
overnight at 4◦C with primary antibodies, rabbit anti-EM2
(1:200; Chemicon, Temecula, CA, USA) and guinea pig anti-
MOR (1:500; Abcam, Cambridge, MA, USA). Then, the
sections were washed with phosphate-buffered saline (PBS)
and incubated with Alexa488-conjugated donkey anti-rabbit
IgG (1:500; Invitrogen, Carlsbad, CA, USA) and Alexa594-
conjugated donkey anti-guinea pig IgG (1:500; Invitrogen) for
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6 h. Finally, the sections were rinsed with PBS, mounted onto
clean glass slides, air-dried and coverslipped with a mixture
of 0.05 M PBS containing 50% (v/v) glycerin and 2.5% (w/v)
triethylenediamine. The sections were viewed under a confocal
laser scanning microscope (FV-1000, Olympus, Tokyo, Japan).
The images were captured and analyzed using Fluoview 1000
(Olympus).
ELISA
Experiments were carried out according to a previous protocol
(Marténez-Lorenzana et al., 2008). Brain, lumbar spinal cord,
cerebrospinal fluid (CSF) and plasma samples were collected
to quantify the EM2 concentration with different experimental
conditions. CSF (n = 6 in each group) was taken from the
cisterna magna at different times, and the samples were stored
at −70◦C for subsequent analyses. After CSF samples were
obtained, 1.0 ml of blood was collected from the heart and
stored in chilled Eppendorf tubes containing 1.0 mg EDTA.
Blood samples were centrifuged at 0◦C, 1600 rpm for 15 min,
and the plasma was harvested and stored at −70◦C. Then,
tissues from the lumbar spinal cord (L4–L6) and brain from
each rat were removed and homogenized in a solution of
50 mM Tris–HCl (pH 9) containing protease inhibitors. After
centrifugation for 30 min at 4◦C, the supernatants were collected,
and the protein content was determined. EM2 concentrations
in the brain, lumbar spinal cord, CSF and plasma samples were
analyzed using an enzyme immunoassay (EIA) kit (Phoenix
Pharmaceuticals, Inc., EK-044-11). For each EIA sample for each
rat, 100 µl of CSF was used. The instructions supplied with
the EM2 EIA kit were followed without modification, and EM2
was measured directly in the plasma, CSF, brain and spinal
cord tissue samples. The data from a microplate ELISA reader
were analyzed using an ELISA reader (Bio-Rad, iMark, Hercules,
CA, USA).
Western Blotting
Rats (n = 6 in each group) were killed under pentobarbital
anesthesia. The lumbar spinal dorsal horn and the L4–L6
dorsal root ganglions (DRGs) were homogenized in lysis
buffer containing proteinase inhibitors and phosphatase
inhibitors (Roche, Switzerland). Then, the homogenized samples
were centrifuged at 12,000× g for 10 min at 4◦C. Next, the
lysate protein concentrations were determined with a BCA
protein assay kit (Pierce, Appleton, WI, USA), mixed with
5× sodium dodecyl sulfate (SDS) sample buffer, and boiled
for 10 min. Equal samples of protein from animals were
electrophoresed by SDS-PAGE in 12% polyacrylamide gel
and transferred to PVDF membranes (Millipore, Bedford,
MA, USA). Then, membranes were blocked with 5% bovine
serum albumin (BSA) and incubated overnight at 4◦C with
primary antibodies, including anti-MOR (rabbit polyclonal,
1:500; Abcam), anti-phosphorylated-MOR (Ser375, rabbit
polyclonal, 1:1000; Cell Signaling Technology, Beverly,
MA, USA) and anti-β-actin (mouse monoclonal, 1:2000;
Sigma). After incubation of the membrane with peroxidase-
conjugated anti-rabbit secondary antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 2 h at room
temperature, the reaction products were visualized with
enhanced chemiluminescence (Amersham Life Science,
Amersham, UK). Western blots were made in triplicate.
Band density was measured and normalized against a loading
control band.
Intrathecal Injection
Intrathecal implantation was performed as our reports have
previously described (Mei et al., 2011; Kou et al., 2013).
The polyethylene (PE) tube (Becton Dickinson and Company,
Franklin Lakes, NJ, USA) was inserted directly into the
subarachnoid space of the lumbar enlargement (L4–L6). Briefly,
under pentobarbital anesthesia, a midline incision was made
at the back of the rat. A pre-measured length of PE10 tube
(I.D. 0.28 mm and O.D. 0.61 mm) was passed caudally at
the level of the lumbar vertebra. After administration of 2%
lidocaine (10 µl) through the intrathecal catheter, only rats
that showed complete paralysis of the tail and bilateral hind
legs and full recovery from the paralysis 30 min after lidocaine
injection were judged to be neurologically normal. After tube
implantation, rats were allowed to recover for 2 days. Rats were
intrathecally injected with either EM2 (20 µg) or 10 µl saline
for a control through the catheter from 10:00 am to 10:30
am per day for 14 days (Zadina et al., 1997; Horvath et al.,
1999).
Electrophysiological Study
Slice Preparation
Fourteen days after STZ injection, rats with significant
mechanical allodynia were anesthetized with 7% chloralic hydras
and then perfused transcardially for 2 min with 100 ml
of ice-cold sucrose-substituted artificial CSF (sucrose ACSF:
220 mM sucrose, 2.5 mM KCl, 0.5 mM CaCl2, 6.0 mM
MgSO4·7H2O, 1.2 mM NaH2PO4, 26 mM NaHCO3, 10 mM
glucose, 1 mM ascorbate and 3.0 mM pyruvate, 290–330
mOsm, pH 7.25–7.45; Chen et al., 2015a). A laminectomy was
performed to remove the lumbar spinal cord. Transverse slices
of L4–L5 spinal segments (400 µm) were cut on a vibrating
microtome (Leica VT 1200s, Heidelberger, Nussloch, Germany)
in ice-cold sucrose ACSF. Then, the slices were collected in
an incubation chamber filled with normal ACSF (124 mM
NaCl, 2.5 mM KCl, 2 mM MgSO4·7H2O, 2 mM CaCl2, 1 mM
NaH2PO4, 25 mM NaHCO3, 25 mM glucose, 1 mM ascorbate
and 3.0mMpyruvate) and incubated for 1 h at room temperature
(22–25◦C). All the ACSF solutions in this experiment were
continuously equilibrated with the carbogen gas (95% O2 and
5% CO2).
Electrophysiological Recordings
Each spinal cord slice was transferred to recording chambers,
fixed with parallel nylon threads, and supported by a U-shaped
platinum weight. The slice was continuously perfused with
ACSF at 2–3 ml/min. Neurons in the lamina II of the
spinal cord slice were identified with differential interference
contrast/infrared illumination on a fixed-stage microscope
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(BX51W1; Olympus, Tokyo, Japan). Voltage-clamp recording
procedures were used as described previously (Yang et al.,
2001; Chen et al., 2011, 2015a). Currents were recorded from
lamina II neurons at a holding potential of −70 mV using
an internal pipette solution containing the following reagents:
130 mM potassium gluconate, 5 mM NaCl, 15 mM KCl, 0.4 mM
EGTA, 10 mM HEPES, 4 mM Mg-ATP and 0.2 mM Tris-
GTP. The solution was adjusted to pH 7.2–7.4 with 1 M
KOH, and the osmolality was adjusted to 290–300 mOsm.
Recordings of spontaneous excitatory postsynaptic currents
(sEPSCs) began approximately 10–15 min after whole-cell
access was established and the current reached a steady state.
The input resistance was monitored, and the recording was
abandoned if it changed by more than 15%. All signals were
recorded using aMultiClamp 700B amplifier (Axon Instruments,
Forster City, CA, USA). The data were recorded using the
software pClAMP 10.2 (Axon Instruments). To examine the
effects of EM2 on sEPSCs, a concentration of 3 µM EM2
(Sigma) was perfused through the bath solution (Chen et al.,
2015a).
Statistical Analyses
The results from immunohistochemistry were obtained as
detailed in previous reports (Fernyhough et al., 1989; Aizawa
and Eggermont, 2006; Zuo et al., 2011; Kou et al., 2013). In
the spinal dorsal horn, the relative optical density (ROD, the
control group was set as 100%) was used for statistical analysis
as in our previous reports (Zuo et al., 2011; Kou et al., 2013,
2014). Analysis of the time course of behavior tests between
saline- and EM2-treated groups was performed by a two-
factor (group and time) repeated-measures analysis of variance
(ANOVA). The data were expressed as the mean ± SD and
were analyzed by SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
The data from Western blotting and ELISA were analyzed with
a one-way ANOVA with the Student–Newman–Kuels (SNK)
post hoc test. The results from patch-clamp recordings were
presented as the mean ± SEM and analyzed as previously
reported (Kohno et al., 2005; Chen et al., 2011, 2015a). The
frequency and amplitude of sEPSCs were analyzed using a
peak detection program (MiniAnalysis; Synaptosoft, Decatur,
GA, USA). The cumulative probability of the amplitude,
time decay and inter-event interval of sEPSCs was compared
by using the Komogorov-Smirnov test. The effects of EM2
on sEPSCs were determined using a paired or unpaired
Student’s t-test, and p < 0.05 was considered statistically
significant.
RESULTS
STZ-Induced Type 1 Diabetic Rats
Following an injection of STZ, we examined changes in the
blood glucose and body weight of rats for 28 days. There was
no difference in basal blood glucose concentration between
STZ-treated rats and control rats at the onset of the study
(7.55 ± 0.83 mM vs. 7.75 ± 0.86 mM in the control group,
p > 0.05, Figure 1A). On the 3rd day, compared with control
rats, rats treated with STZ exhibited significant hyperglycemia
(27.78 ± 1.88 mM vs. 7.88 ± 0.69 mM in the control group,
p < 0.05) until day 28 (30.07 ± 1.00 mM vs. 7.75 ± 0.49
mM in the control group, p < 0.05, Figure 1A). Additionally,
the body weights of the diabetic rats were significantly lower
than those of the control rats on day 14 (213.33 ± 9.83
g vs. 322.50 ± 15.41 g in the control group, p < 0.05)
and continued thereafter until day 28 (211.67 ± 8.76 g vs.
371.67 ± 8.16 g in the control group, p < 0.05, Figure 1B).
The results indicate that rats injected with STZ developed
type 1 diabetic features including hyperglycemia and body
weight loss.
Mechanical Allodynia in STZ-Induced Type
1 Diabetic Rats
Fourteen days after diabetes onset, when tested with von Frey
filaments, the PWTs in diabetic rats were significantly lower
than those in control rats (4.33 ± 1.97 g vs. 11.33 ± 2.94 g in
the control group, p < 0.05, Figure 1C). On day 28, there was
a significant difference between the diabetic rats and controls
(2.90 ± 1.76 g vs. 11.00 ± 3.22 g in the control group, p < 0.05,
Figure 1C). The behavioral results suggest that mechanical
allodynia developed in STZ rats on day 14 but peaked on day 28,
along with an increased blood glucose level and reduced body
weight (Figure 1C).
FIGURE 1 | Streptozotocin (STZ)-induced diabetic rats exhibit elevated blood glucose concentration, reduced body weight and decreased paw
withdrawal thresholds (PWTs). Changes in blood glucose concentration (A), body weight (B) and PWTs (C) in rats after STZ injection from day 3 to day 28.
Mean ± SD, n = 6 per group, ∗p < 0.05 vs. non-diabetic control rats.
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FIGURE 2 | Photomicrographs indicate the localization of
endomorphin-2 (EM2) and µ-opioid receptor (MOR) in the spinal cord.
Fluorescent photographs show how EM2-immunopositive (IP) and MOR-IP
terminals are distributed in the spinal dorsal horn (A). Scale bar: 100 µm in
(A). Statistical analysis of the relative optical density (ROD) of EM2-IP terminals
(B) and MOR-IP terminals (C) in different groups. The sample of the control
group was set at 100%. Mean ± SD, n = 6 per group, ∗p < 0.05 vs.
non-diabetic control rats.
Changes in EM2 and MOR in the Spinal
Dorsal Horn of Diabetic Rats
First, we investigated the expression of EM2 and MOR in
the spinal cord during the progressive mechanical allodynia
by immunohistochemistry. The EM2-positive terminals were
densely observed in the superficial layer of the spinal dorsal
horn (Figure 2A). Our results showed that EM2-positive
puncta in laminae I and II of the spinal cord in diabetic rats
decreased gradually but significantly from day 14 (85.4% of
control, p < 0.05) to day 28 (70.1% of control, p < 0.05,
Figures 2A,B). In the spinal cord, MOR-labeling was also found
in the dorsal horn (Figure 2). Accompanied by the reduced
expression of EM2, there was amarked decrease inMOR-positive
terminals on day 14 (76.3% control, p < 0.05) and on day
28 (56.6% of control, p < 0.05, Figures 2A,C) in the spinal
dorsal horn.
Second, we observed the changes in EM2 concentration in
the brain, lumbar spinal cord, CSF and plasma in diabetic rats
by ELISA. The results showed that diabetic rats had markedly
lower EM2 concentrations in brain tissue on day 14 (1.86 ± 0.03
pg/ml) and day 28 (1.80 ± 0.02 pg/ml) compared with the
control group (2.21 ± 0.37 pg/ml, p < 0.05, Figure 3A). In
the lumbar spinal cord, the concentrations of EM2 significantly
decreased in diabetic rats: 0.64± 0.01 pg/ml on day 3 (p< 0.05),
0.58 ± 0.002 pg/ml on day 14 (p < 0.05) and 0.49 ± 0.02
pg/ml on day 28 (p < 0.05, Figure 3B). As demonstrated in
Figure 3C, EM2 concentrations in CSF decreased substantially
in diabetic rats on day 3 compared with controls (2.40 ± 0.02
pg/ml, p < 0.05) and remained at the reduced level on day
28 (1.52 ± 0.03 pg/ml, p < 0.05). No significant variation
in EM2 concentration was observed in the plasma (p > 0.05,
Figure 3D).
FIGURE 3 | EM2 concentrations in the brain (A), lumbar spinal cord (B),
cerebrospinal fluid (CSF; C) and plasma (D) in control and diabetic
rats. Values are expressed as pg/ml. Mean ± SEM, n = 6 per group,
∗p < 0.05 vs. non-diabetic control rats.
Third, the data from Western blotting indicated a significant
decrease in MOR expression from day 14 in the spinal cord
of diabetic rats (67.1% of control, p < 0.05, Figures 4A,C).
Compared with the controls, the diabetic rats showed a reduced
level of MOR on day 28 (47.3% of control, p < 0.05,
Figures 4A,C). Because MORs in the spinal dorsal horn
mainly originate from the central axons of the DRG, we
also examined the changes in MOR in the DRG. The
expression of MOR decreased significantly from day 14 (43.9%
of control, p < 0.05, Figures 4B,D) to day 28 (14.3% of
control, p < 0.05, Figures 4B,D). These results suggest that
the decrease in EM2 and MOR in the spinal cord was
consistent with the progressive mechanical allodynia in diabetic
rats.
Effects of Intrathecal Injection of EM2 on
Mechanical Allodynia
To detect the effects of EM2 on PDN, EM2 was injected
intrathecally once a day from day 14 to day 28 in the STZ-
induced type 1 diabetic rats. According to previous reports
(Zadina et al., 1997; Janecka et al., 2008), EM2 (20 µg) or
saline was applied through intrathecal injection for 14 days.
The PWTs were examined within 30 min after injection,
from day 7 to day 28 (Figure 5A). After EM2 treatment,
the PWTs in diabetic rats were elevated significantly on day
16 (p < 0.05, compared with that of the STZ-saline group,
Figure 5B). Moreover, 14-day treatment with EM2 apparently
increased PWTs in diabetic rats on day 28 (6.00 ± 1.26 g
vs. 2.57 ± 1.70 g in STZ-saline group, p < 0.05, Figure 5B).
However, we found that intrathecal administration of EM2
could not fully attenuate mechanical allodynia in diabetic rats
compared with control rats treated with saline (p < 0.05,
Figure 5B).
After EM2 administration, the results from Western blotting
demonstrated that intrathecal EM2 treatment significantly
increased the expression of MOR in the spinal cord of diabetic
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FIGURE 4 | The expression of MOR was detected in the spinal cord (A)
and the dorsal root ganglion (DRG; B) by Western blotting. Statistical
analysis of MOR in the spinal cord (C) and the DRG (D) in different groups.
The sample of the control group was set at 100%. Mean ± SD, n = 6 per
group. ∗p < 0.05 vs. non-diabetic control rats.
rats (p < 0.05, compared with that of the STZ-saline group,
Figures 6A,B). Moreover, the tendency for reduced pMOR
levels was partially attenuated after EM2 treatment (p < 0.05,
compared with that of the STZ-saline group, Figures 6A,C),
suggesting that EM2 application attenuated the down-regulation
of MOR in the spinal cord and alleviated mechanical allodynia in
STZ-induced type 1 diabetic rats.
Effects of EM2 on Glutamatergic Input to
Spinal Dorsal Horn Neurons in Diabetic
Rats
MOR localized in primary central terminals is essential for
EM2 analgesia in the spinal cord (Sakurada et al., 1999, 2001;
Chen et al., 2015b). One of the mechanisms is presynaptic
inhibition of the release of neurotransmitters, especially the
release of glutamate (Fujita and Kumamoto, 2006; Fichna et al.,
2007). In the present study, we found that the expression of
MOR was down-regulated in the DRG neurons and spinal
cord. Next, to determine the consequence of the reduced
MOR exerted on glutamate release, we compared the effects
of EM2 on recordings of sEPSCs in lamina II neurons
(Figure 7A). The results indicated that the baseline frequency
of glutamatergic sEPSCs was significantly higher in diabetic
rats than in control rats (p < 0.05, 5.31 ± 0.6 Hz vs.
2.72 ± 0.39 Hz, unpaired Student’s t-test, Figures 7B,D).
Perfusion of 3 µM EM2 resulted in a rightward shift in
the distribution of the inter-event interval of glutamatergic
sEPSCs in the two groups (control rats: 1.82 ± 0.32 Hz;
diabetic rats: 3.94 ± 0.52 Hz, Figures 7C,D). However, the
amplitude and the decay time between the sEPSCs of control
and diabetic rats did not change significantly (p > 0.05,
paired Student’s t-test, Figures 7C,E,F). These results suggest
that EM2 decreased the frequency, but not the amplitude of
sEPSCs in lamina II neurons. Because the baseline frequency
FIGURE 5 | Effects of intrathecal EM2 on mechanical sensitivity in
diabetic rats compared with the controls. PWTs were measured before
(baseline), day 7, 14, 16, 18, 20, 22, 24, 26 and 28 (A). Intrathecal injection of
EM2 from day 14 to day 28 alleviated the mechanical allodynia (B) in the
diabetic rat. Mean ± SD, n = 6 per group, ∗p < 0.05 vs. STZ rats-saline
group at corresponding time points, #p < 0.05 vs. control-saline group at
corresponding time points.
of sEPSCs in control rats was significantly different from
the diabetic rats (Figure 7D), we normalized the effect of
EM2 to the baseline of sEPSCs (post-drug/pre-drug) in each
trace and then summarized and compared the ratio values
(Kohno et al., 2005). The results showed that EM2 caused a
lower decrease in the frequency of sEPSCs in diabetic rats
than in control rats (p < 0.05, unpaired Student’s t-test,
Figure 7G). At the end of the recording, bath application of
10 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, AMPA
receptor antagonist) blocked the frequency and amplitude of
sEPSCs of the neurons (n = 3/group, data not shown), which
further confirmed that the sEPSCs were glutamate-mediated
postsynaptic currents.
DISCUSSION
Decreased EM2 and MOR in the Spinal
Dorsal Horn are Associated with
Progressive PDN in Diabetic Rats
The distributions of EM2-ir structures, including neuronal cell
bodies, dendritic processes, axonal fibers and terminals, in
the nervous system have been studied extensively (Hosohata
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FIGURE 6 | Effects of intrathecal EM2 on MOR and pMOR in the spinal
dorsal horn. Intrathecal injection of EM2 attenuated the reduction in MOR
and pMOR after 14 days of administration (A). Statistical analysis of MOR (B)
and pMOR (C) in different groups. The sample of the control group was set at
100%. Mean ± SD, n = 6 per group, ∗p < 0.05 vs. STZ rats-saline group at
corresponding time points, #p < 0.05 vs. control-saline group at
corresponding time points.
et al., 1998; Martin-Schild et al., 1999). In contrast to EM1-
ir structures, which are predominantly located in the brain,
EM2-ir structures are mainly observed in the spinal cord
(Hui et al., 2010). On the other hand, when intrathecally
injected, EM2 plays more efficient analgesic roles than EM1
does (Tseng et al., 2000). Our immunochemical findings
showed that EM2-ir terminals were densely located in the
superficial laminae (laminae I and II) of the spinal dorsal
horn. Moreover, the expression of EM2 decreased significantly
in diabetic rats, which was consistent with the development
of mechanical allodynia from day 14–28. We also used
ELISA to detect EM2 concentrations in the spinal cord,
and the results confirmed that the reduction of EM2 in
the spinal cord was in line with the progressive PDN in
diabetic rats.
The next stage was to consider the relationship between
PDN and decreased EM2 in the spinal dorsal horn in diabetes.
We found that EM2 levels were correlated with progressive
mechanical allodynia from day 14–28; the EM2 concentration
decreased significantly in the brain, lumbar spinal cord and CSF
of diabetic rats. However, in contrast to EM2 changes in the
brain, the changes in EM2 concentrations in the spinal cord
and CSF occurred as early as day 3 in the diabetic model,
indicating that diabetes affects EM2 at the initial stage of PDN
in the spinal cord. Previous reports indicate that in diabetic
patients and animals, poor blood glucose control might result
in the reduced inhibition of EM2 in gastrointestinal disorders
(Wang et al., 2014). EM2-immunopositive (IP) terminals in
the spinal dorsal horn principally originate from the central
axons of the attached DRGs (Hui et al., 2010), which belong
to the peripheral nervous system (PNS) and are thus more
sensitive to high glucose in the periphery. This peripheral
localization of the DRGs might be the most important reason
among all of the possible reasons for the early decreased
EM2 levels in the spinal cord. We noted that the tendency
for reduced EM2 concentrations could be found in the
plasma in diabetic rats; however, statistical analyses suggest
that there was no significant difference among groups. We
chose the early stage (14–28 days) of diabetes in the present
study to investigate the mechanism of PDN; therefore, the
unchanged EM2 in the plasma may be associated with a
time delay. These results indicate that the reduction in EM2
levels in the spinal dorsal horn occurs at the early stage
of diabetes, which might be correlated with the progressive
PDN.
Presynaptic MOR may be Involved in the
Decreased Inhibition of EM2 in the Spinal
Dorsal Horn Related to PDN
MOR is the principal endogenous receptor in the spinal
cord that responds to EM2 and is involved in the
antinociception induced by EM2. Our results indicate that,
similar to EM2 distribution, the expression of MOR was
concentrated in the superficial layer of the spinal dorsal
horn (Zadina et al., 1997; Wang et al., 2003; Greenwell
et al., 2007). In diabetic rats, our immunohistochemistry
analyses provided evidence that the expression of MOR
was reduced significantly, along with the decrease in
EM2 expression in the spinal dorsal horn, indicating that
MOR may be involved in antinociception produced by
EM2 in PDN.
In the spinal cord, EM2 binds and activates MOR at both
pre- and postsynaptic sites to drive Gαi/o protein, leading to
the blockade of Ca2+ channels and/or the activation of K+
channels, the suppression of transmitter release and membrane
hyperpolarization (Fichna et al., 2007; Sesena et al., 2014;
Chen et al., 2015b). Particularly at presynaptic sites, EM2 can
decrease the excitability of neurons and inhibit the release
of glutamate (Glu), substance P (SP) and calcitonin gene-
related peptide (CGRP) through the activation of presynaptic
MOR on primary afferent fibers in the spinal dorsal horn
(Fichna et al., 2007). Based on patch-clamp recording, our
results showed that the frequency of glutamatergic sEPSCs
was significantly higher in diabetic rats than in control rats,
suggesting that the glutamate release from the primary afferents
that acts on neurons in the spinal dorsal horn may increase
on day 14, which may contribute to the hyperexcitability
of the dorsal horn neurons in PDN. We found that EM2
inhibited sEPSCs less in diabetic than in control rats; hence,
in response to EM2, MOR activity at the primary afferent
terminals may be down-regulated in PDN. In contrast to
frequency, there was no significant difference in the amplitude
of sEPSCs between diabetic rats and controls. Therefore,
compared to postsynaptic receptors, presynaptic MORs may
play a more important role in the regulation of nociception
and antinociception exerted by EM2 on neurons in the spinal
dorsal horn.
In the spinal dorsal horn, MORs localized at presynaptic
sites are mainly derived from the central axons of the DRG
(Zhou et al., 2014; Honsek et al., 2015), and therefore, we
investigated the changes in MOR expression byWestern blotting
in the spinal cord and the DRG. The results indicate that from
day 14, the protein levels of MOR were reduced significantly
in diabetic rats in both the spinal cord and the DRG. Thus,
rather than postsynaptic MORs, presynaptic MORs may exert a
major effect on the inhibition of EM2 in the spinal dorsal horn
related to PDN.
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FIGURE 7 | Effects of EM2 on glutamatergic spontaneous excitatory postsynaptic currents (sEPSCs) of neurons in spinal lamina II in the control and
diabetic rats. A neuron of lamina II pictured during whole-cell patching (A). The illustrated representative traces of sEPSCs at baseline, with application of 3 µM
EM2 in a neuron of lamina II from a control and a diabetic rat (B). Cumulative fraction of the inter-event interval, time decay and amplitude of sEPSCs (C) during
baseline (blue) and application of EM2 (red) in the control and diabetic rats in the same neurons shown in (B). Analyses of all data in 15 neurons from six control rats
and 14 neurons from 10 diabetic rats illustrated that the frequency was significantly higher in the diabetic rats (D), but there were no differences in decay time (E) and
amplitude (F) between the two groups of rats. Application of EM2 decreased the frequency (D) but not the time decay (E) or the amplitude (F) of the sEPSCs. The
bar chart shows that the frequency of sEPSCs was significantly reduced by EM2, but the inhibitory effects of EM2 were lower in diabetic rats (G). Mean ± SEM,
∗p < 0.05, ∗∗p < 0.01.
EM2 Treatment Partially Alleviates PDN at
the Early Stage of Diabetes
Previous reports suggest that EM2 induces MOR endocytosis
and may act as a feedback mechanism to activate MOR
mRNA transcription, whereas morphine treatment decreases
MOR membrane density (McConalogue et al., 1999; Yu
et al., 2003). Therefore, we delivered EM2 intrathecally as
a treatment for 14 days starting with day 14 and observed
the effects of EM2 on behavioral tests and MOR activity
in diabetic rats. Our results demonstrate that the intrathecal
injection of EM2 could significantly alleviate the mechanical
allodynia in diabetic rats, suggesting that EM2 treatment may
be an effective way to alleviate PDN at the early stage of
diabetes.
Moreover, after EM2 treatment, diminished MOR expression
was partially recovered in the spinal cord. Previous reports
suggest that endogenous opioid peptides stimulate a selective
phosphorylation of the carboxyterminal residue 375 (Ser375;
Schulz et al., 2004; Doll et al., 2011; Grecksch et al., 2011).
Application of EM2 effectively attenuated the decreased pMOR
(Ser375) in diabetic rats on day 14, suggesting that the attenuated
MOR activity may be associated with EM2 application.
CONCLUSION
In summary, our findings showed a reduction in EM2 and MOR
expression in the spinal dorsal horn in STZ-induced diabetic
rats with progressive mechanical allodynia. The diminished
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EM2 and reduced MOR activity at presynaptic sites in the
spinal dorsal horn may be involved in the early stage of the
development of PDN.
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